SoftBank Ventures Invests in AI Precision Medicine Company Imprimed
Leading Series A Round Investment Worth 30 Billion Won
SoftBank Ventures announced on the 22nd that it has led the Series A investment in Imprimed, an artificial intelligence (AI) precision medicine company located in Silicon Valley. This round of investment, totaling 30 billion KRW, included participation from prominent investors such as SoftBank Ventures, Hanriver Partners, SK Telecom, KDB Silicon Valley, Ignite Innovation Fund, Samyang Chemical Group, Murex Partners, Byucksan, and Mayo Clinic, which is recognized as the top hospital in the United States. The total cumulative investment amount is 45 billion KRW.
Imprimed is a startup founded in Silicon Valley by co-founders Sungwon Lim, CEO, and Jamin Koo, CTO, who completed their undergraduate and doctoral studies together at KAIST and Stanford University. The company provides patient-tailored anticancer drug efficacy prediction services using AI technology.
In particular, Imprimed’s "Customized Predictive Profiling" service analyzes various biological characteristics of cancer cells in dogs with blood cancer through AI models to predict the response and prognosis of each anticancer drug, determining which treatment is most effective. This service is currently being used by oncology-specialized veterinarians at over 250 animal hospitals across the United States for more than 4,700 dogs.
Through this investment, Imprimed plans to advance the development and commercialization of precision medicine services not only for pets but also for cancer patients. The company has currently secured precision medicine support technology for people suffering from leukemia and lymphoma. Regarding the prognostic and predictive testing software for multiple myeloma, it has been selected as an innovative medical device by the Ministry of Food and Drug Safety and is undergoing the approval process with the goal of commercialization next year.
Hot Picks Today
Up to 600 Million Won for Semiconductors, 160 Million Won Bonus for Loss-Making Non-Memory… Samsung Electronics Labor and Management Reach Tentative Deal on Unprecedented Performance Compensation (Comprehensive)
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- U.S. Stocks Up 1% on War Negotiation Hopes... Will Korea Recover Recent Losses? [Good Morning Market]
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Sungwon Lim, CEO of Imprimed, stated, "We will rapidly apply the know-how gained from services for dogs to the research and development of services for human cancer patients and become a leading platform company in the precision medicine market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
